HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regular Aspirin Use To Prevent Cardiovascular Events Not Advisable For Most Patients – ACC/AHA Guidelines

Executive Summary

Aspirin should be used very selectively in the primary prevention of artherosclerotic cardiovascular disease, according to new guidelines from the American College of Cardiology and American Heart Association. While certain higher-risk adults may benefit from regular, preventative aspirin use, those over the age of 70, and any at increased risk of bleeding, should explore lifestyle changes, the groups say.

You may also be interested in...



Breast Cancer Study Finds Benefit From Aspirin Use Linked To DNA Profiles

Breast cancer mortality among women who regularly used aspirin decreased 22%-40% for those with unmethylated tumor promoter and progesterone receptor genes, while women with methylated tumor promoter had of 67% all-cause death risk, study finds. Researchers and editorial author say study underscores importance of looking at methylation profiles, or chemical changes, in tumor tissue DNA.

‘Widespread’ Aspirin Use To Prevent CVD By Consumers At Risk Of Harm, NHIS Data Show

Aspirin use to prevent CVD "widespread" among US adults who should not use it regularly, according to analysis of 2017 National Health Interview Survey. Nearly half of adults 70 and up without self-reported CVD take aspirin even though guidelines recommend against routine use by persons that age and those with increased bleeding risk.

ASPREE Results Support FDA Aspirin Label Guidance On Cardiovascular Disease

Data from ASPREE trial with more than 19,000 subjects show five-year-use of low-dose aspirin did not prolong disability-free survival and is associated with a significantly higher rate of hemorrhage and somewhat higher rate of all-cause mortality. Findings in three reports in NEJM track with US FDA's guidance that OTC aspirin marketers include a statement referring to doctors when aspirin package labels include a heart or other image suggesting a CV indication.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148638

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel